Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, today announces that it has received approval from the Chinese State Food and Drug Administration ("SFDA") for its MedicRead Colon workstation.  Medicsight will launch this workstation via a Chinese dealer network which gives the Company access to almost 1000 sales representatives.

David Sumner, Chief Executive of Medicsight, commented: "This is another significant milestone for Medicsight and we are delighted to have received approval from the SFDA.  China is one of the world's fastest growing medical imaging markets and is one of Medicsight's core target markets, with a high installed base of MDCT (Multidetector Computed Tomography), high incidence of colorectal cancer and a large population.  In readiness for this approval, Medicsight has been working closely with its Chinese dealer network in preparation for the national launch in Guangzhou during the May Chinese Society of Abdominal Radiology congress."

President Qi Ji, President of the Chinese Society of Radiology, said "We have been working with Medicsight for 3 years as part of their Chinese clinical programme.  We have been delighted with the performance of Medicsight's products, which have proven to make a marked difference in the speed and accuracy of our diagnosis.  As the number of patients in China increases, CAD software is becoming increasingly important for radiologists where improved workflow and productivity support their efforts to save lives.  I am delighted that Medicsight's products will now be available to radiologists across China."

MedicRead Colon is an advanced visualisation workstation for CT Colonography and combines Medicsight's ColonCAD computer-aided detection technology with 3D imaging tools to assist radiologists in the detection of colorectal neoplasia (polyps).  This software reduces the workload of radiologists by automatically highlighting suspicious areas on scan images, and may also help radiologists detect possibly malignant tumours at an early stage when treatment is most likely to be successful.

For further information:
Medicsight PLC
David Sumner
Tel: +44 (0)20 7605 7950
www.medicsight.com

Collins Stewart Europe Limited
Tim Mickley
Tel: +44 (0)20 7523 8350
Tel: +44 (0)20 7523 8302

Media enquiries:
Abchurch
Tel: +44 (0) 20 7398 7700
Ashley Tapp
Tel: +44 (0) 20 7398 7718
ashley.tapp@abchurch-group.com

Stephanie Cuthbert
Tel: +44 (0) 20 7398 7712
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

Notes to editors
About Medicsight
Medicsight PLC is a UK-headquartered, research-driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's computer-aided detection (CAD) software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD™ and LungCAD™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome.

About Medicsight's CAD software
Medicsight's ColonCAD™ and LungCAD™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.